USA > Japan based Astellas Pharma Inc. acquires US based Mitobridge for $225 million (plus additional $225 million contingent on clinical development)

Astellas_Pharma_logo.svg Exercising its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function, Astellas Pharma Inc. will now wholly own US based Mitobridge. The 2013 partnership agreements between Astellas and Mitobridge were formulated to discover and develop compounds that More …